Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
PPHMP was delisted on the 5th of January, 2018.
0 hedge funds and large institutions have $0 invested in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $4.34M → $0 (-$4.34M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$4.34M |
PPHMP Hedge Fund Activity: Q2 2017 in Review
0 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) for Q2 2017, worth a combined $0 — down 100% from $4.34M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PPHMP and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Perceptive Advisors, exiting entirely with an estimated $4.34M sold.
- 0 institutional investors held Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) as of Q2 2017, down from 1 in Q1 2017.
- Funds reported $0 of Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible stock for Q2 2017, down 100% quarter-over-quarter.
- 0 funds opened new Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible positions in Q2 2017 and 1 closed out, a net change of -1 holder.
- The largest Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible seller in Q2 2017 was Perceptive Advisors, an estimated $4.34M sold.
Based on aggregated 13F filings for Q2 2017.